Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

APOE polymorphism and the progression of diabetic nephropathy in Japanese subjects with type 2 diabetes: results of a prospective observational follow-up study.

Araki S, Koya D, Makiishi T, Sugimoto T, Isono M, Kikkawa R, Kashiwagi A, Haneda M.

Diabetes Care. 2003 Aug;26(8):2416-20.

PMID:
12882872
2.

The relationship of the apolipoprotein E gene polymorphism Turkish Type 2 diabetic patients with and without nephropathy.

Erdogan M, Eroglu Z, Biray C, Karadeniz M, Cetinkalp S, Kosova B, Gunduz C, Topcuoglu N, Ozgen G, Yilmaz C.

J Endocrinol Invest. 2009 Mar;32(3):219-22.

PMID:
19542737
3.

Type 2 diabetes mellitus and its renal complications in relation to apolipoprotein E gene polymorphism.

Ma SW, Benzie IF, Yeung VT.

Transl Res. 2008 Sep;152(3):134-42. doi: 10.1016/j.trsl.2008.07.003. Epub 2008 Aug 12.

PMID:
18774543
4.

The presence of apolipoprotein epsilon4 and epsilon2 alleles augments the risk of coronary artery disease in type 2 diabetic patients.

Vaisi-Raygani A, Rahimi Z, Nomani H, Tavilani H, Pourmotabbed T.

Clin Biochem. 2007 Oct;40(15):1150-6. Epub 2007 Jul 6.

PMID:
17689519
5.

Apolipoprotein E polymorphism and expression in type 2 diabetic patients with nephropathy: clinicopathological correlation.

Guan J, Zhao HL, Baum L, Sui Y, He L, Wong H, Lai FM, Tong PC, Chan JC.

Nephrol Dial Transplant. 2009 Jun;24(6):1889-95. doi: 10.1093/ndt/gfn734. Epub 2009 Feb 14.

PMID:
19218599
6.

Higher frequency of apolipoprotein E2 allele in type 2 diabetic patients with nephropathy in Taiwan.

Hsieh MC, Lin SR, Yang YC, Chen HC, Lin JN, Shin SJ.

J Nephrol. 2002 Jul-Aug;15(4):368-73.

PMID:
12243365
7.

Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study.

Hadjadj S, Belloum R, Bouhanick B, Gallois Y, Guilloteau G, Chatellier G, Alhenc-Gelas F, Marre M.

J Am Soc Nephrol. 2001 Mar;12(3):541-9.

8.

Association between apolipoprotein E genetic polymorphism and the development of diabetic nephropathy in type 2 diabetic patients.

Kwon MK, Rhee SY, Chon S, Oh S, Woo JT, Kim SW, Kim JW, Kim YS, Jeong KH, Lee SH, Lee TW, Ihm CG.

Diabetes Res Clin Pract. 2007 Sep;77 Suppl 1:S228-32. Epub 2007 Jul 12.

PMID:
17624465
9.

Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy.

Tarnow L, Stehouwer CD, Emeis JJ, Poirier O, Cambien F, Hansen BV, Parving HH.

Nephrol Dial Transplant. 2000 May;15(5):625-30.

PMID:
10809802
10.

APOE polymorphisms and the development of diabetic nephropathy in type 1 diabetes: results of case-control and family-based studies.

Araki S, Moczulski DK, Hanna L, Scott LJ, Warram JH, Krolewski AS.

Diabetes. 2000 Dec;49(12):2190-5.

PMID:
11118024
11.

Progression to overt nephropathy in type 2 diabetes: the Casale Monferrato Study.

Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Pagano G, Cavallo Perin P; Casale Monferrato Study.

Diabetes Care. 2003 Jul;26(7):2150-5.

PMID:
12832328
12.

Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM.

Kimura H, Suzuki Y, Gejyo F, Karasawa R, Miyazaki R, Suzuki S, Arakawa M.

Am J Kidney Dis. 1998 Apr;31(4):666-73.

PMID:
9531184
13.

Apo E gene polymorphism on development of diabetic nephropathy.

Ilhan N, Kahraman N, Seçkin D, Ilhan N, Colak R.

Cell Biochem Funct. 2007 Sep-Oct;25(5):527-32.

PMID:
16933203
14.

Polymorphisms of the protein kinase C-beta gene (PRKCB1) accelerate kidney disease in type 2 diabetes without overt proteinuria.

Araki S, Haneda M, Sugimoto T, Isono M, Isshiki K, Kashiwagi A, Koya D.

Diabetes Care. 2006 Apr;29(4):864-8.

PMID:
16567829
15.

Association of APOE epsilon2/epsilon3/epsilon4 and promoter gene variants with dementia but not cardiovascular mortality in old age.

Heijmans BT, Slagboom PE, Gussekloo J, Droog S, Lagaay AM, Kluft C, Knook DL, Westendorp RG.

Am J Med Genet. 2002 Jan 22;107(3):201-8.

PMID:
11807900
16.

[Polymorphic gene markers of lipid metabolism are associated with diabetic nephropathy in patients with type 1 diabetes mellitus].

Iakunina NIu, Shestakova MV, Voron'ko OE, Vikulova OK, Sevost'ianov KV, Chugunova LA, Shamkhalova MSh, Dedov II, Nosikov VV.

Genetika. 2005 Jul;41(7):931-7. Russian.

PMID:
16152798
17.

Apolipoprotein E genotype and plasma lipid levels in Caucasian diabetic patients.

Morbois-Trabut L, Chabrolle C, Garrigue MA, Lasfargues G, Lecomte P.

Diabetes Metab. 2006 Jun;32(3):270-5.

PMID:
16799405
18.

Risk factors for the progression of microalbuminuria in Japanese type 2 diabetic patients--a 10 year follow-up study.

Oue T, Namba M, Nakajima H, Ono A, Horikawa Y, Yamamoto K, Hamaguchi T, Fujino-Kurihara H, Yamasaki T, Tomita K, Miyagawa J, Hanafusa T, Matsuzawa Y.

Diabetes Res Clin Pract. 1999 Oct;46(1):47-55.

PMID:
10580616
19.

Apolipoprotein E polymorphism in 385 patients on renal replacement therapy in Sweden.

Roussos L, Ekström U, Ehle PN, Oqvist B, Floren CH.

Scand J Urol Nephrol. 2004;38(6):504-10.

PMID:
15841787
20.

Association between apolipoprotein E polymorphism and macroalbuminuria in patients with non-insulin dependent diabetes mellitus.

Ha SK, Park HS, Kim KW, Kim SJ, Kim DH, Kim JH, Lee HY, Han DS.

Nephrol Dial Transplant. 1999 Sep;14(9):2144-9.

PMID:
10489223

Supplemental Content

Support Center